PT-141 is a lab-made injectable prescription medication acting on brain receptors for sexual interest, appetite and skin color. Approved only for distressing low sexual desire in women before menopause, it modestly raises desire but does not increase satisfying sexual experiences. Nausea is common and each dose briefly raises blood pressure. For men, women after menopause and weight control, evidence is thin and manufacturer-dominated; effects on aging are unmeasured. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | <130/80 mmHg | Uncontrolled hypertension rules out use |
| Resting heart rate | 60–100 beats per minute | Each dose lowers heart rate transiently |
| eGFR | ≥90 mL/min/1.73 m² | Below 30 doubles exposure |
| ALT | 7–55 U/L | Rise prompts stopping |
| Pregnancy test (hCG) | Negative | Positive result stops use |
| Skin and mole examination | No established target; track new or darkening patches against baseline photographs | Hyperpigmentation prompts stopping |
| FSFI desire domain score | No established target; track change from own baseline | Primary efficacy marker |
| Body weight | No established target; track change from own baseline | Expected to change with repeated daily dosing |
| FSDS-DAO item 13 distress score | Decrease of at least 1 point (responder threshold) | Tracks distress about low desire |
| Bilirubin | Not specified in the ER | Paired with ALT for liver safety |
Cadence: Baseline before the first dose; blood pressure 2–4 hours after the first dose, then every 3–6 months; skin examination every 3 months; desire and distress scores at 8 weeks, then every 6 months; liver tests repeated only if symptoms such as jaundice or dark urine appear